B7-H3 ADC

At the forefront of the development of custom immune checkpoint inhibitors (ICIs), Creative Biolabs has emerged as a preeminent provider of innovative ICI development services. The B7-H3 ADC has demonstrated tremendous potential in the preclinical setting, offering a promising avenue for the treatment of cancer and other diseases. We will explore the latest breakthroughs in B7-H3 pathway studies and illuminate the range of related services we offer to our valued clients.

Introduction to B7-H3 ADC

B7-H3, an immune checkpoint protein that is widely expressed in various cancer cells, including breast, ovarian, prostate, and lung cancer, has become increasingly important for its critical role in inhibiting the immune response against cancer cells, leading to tumor cells evading immune surveillance. Thus, B7-H3 has emerged as a highly promising target for cancer immunotherapy due to its involvement in the suppression of immune responses.

Fig. 1 A duocarmycin-based antibody–drug conjugate targeting B7-H3 for solid cancer. (Scribner J A, et al., 2020)

ADCs, a sophisticated class of anticancer therapeutics that merge the selectivity of monoclonal antibodies with the potent cytotoxicity of small molecule drugs, have presented compelling findings in both preclinical and clinical evaluations, catalyzing the approval of multiple ADCs to tackle diverse cancer types.

Advances in Studies of B7-H3 ADC

The development of B7-H3 ADC is a recent breakthrough in cancer immunotherapy. Several studies have shown that B7-H3 is highly expressed in a variety of cancer cells and is associated with poor prognosis. The high expression of B7-H3 in cancer cells makes it an attractive target for ADC therapy.

• The B7-H3 ADC specifically targets B7-H3-expressing cancer cells. The ADC is composed of a monoclonal antibody that recognizes B7-H3 and a potent cytotoxic agent that kills cancer cells upon internalization. The high specificity of the monoclonal antibody ensures that the cytotoxic agent is delivered only to B7-H3-expressing cancer cells, minimizing off-target effects.
• In preclinical studies, the B7-H3 ADC has shown remarkable efficacy in killing B7-H3-expressing cancer cells, both in vitro and in vivo. The ADC has also been shown to induce potent antitumor immune responses, further enhancing its efficacy against cancer cells.

B7-H3 ADC Related Services We Offer

At Creative Biolabs, we offer a wide range of custom ADC development services, including B7-H3 ADC development. Our team of experienced scientists can help you design and develop a B7-H3 ADC that meets your specific requirements.

• We offer a range of services, including antibody production, linker conjugation, and cytotoxic agent selection, to ensure the optimal performance of your ADC.
• We also offer comprehensive preclinical evaluation services to assess the efficacy and safety of your B7-H3 ADC. Our preclinical evaluation services include in vitro cytotoxicity assays, in vivo efficacy studies, pharmacokinetic and pharmacodynamic studies, and toxicology studies.

Advantages of B7-H3 ADC

• The high specificity of the monoclonal antibody ensures that the cytotoxic agent is delivered only to B7-H3-expressing cancer cells, minimizing off-target effects.
• Potent antitumor immune responses.
• Low toxicity profile and remarkable efficacy in preclinical studies.

At Creative Biolabs, our team of skilled and accomplished scientists is fully committed to delivering unparalleled custom ADC development services that cater to the unique requirements of our valued clients. If you are interested in developing a B7-H3 ADC or any other custom ADC, please don't hesitate to contact us. We are always happy to discuss your specific needs and provide a customized solution that meets your requirements.

References

1. Scribner J A, et al. Preclinical Development of MGC018, a Duocarmycin-based Antibody–drug Conjugate Targeting B7-H3 for Solid CancerMGC018, a Duocarmycin-based ADC Targeting B7-H3 for Cancer. Molecular Cancer Therapeutics, 2020, 19(11): 2235-2244.
2. Zou Y, et al. B7-H3 as a novel CAR-T therapeutic target for glioblastoma. Mol Ther Oncolytics, 2019; 14: 279-287.

All listed customized services & products are for research use only, not intended for pharmaceutical, diagnostic, therapeutic, or any in vivo human use.